Limits...
Impact of epoetin beta on quality of life in patients with malignant disease.

Boogaerts M, Coiffier B, Kainz C, Epoetin beta QOL Working Gro - Br. J. Cancer (2003)

Bottom Line: Baseline to final visit changes in SF-36 PCS, FACT-F and VAS scores were significantly greater with epoetin beta than with standard care (P<0.05); changes in FACT-An subscale score tended to be greater with epoetin beta (P=0.076).Epoetin beta significantly increased Hb concentrations relative to standard care (responders: 47% vs 13%; P<0.001).Levels of endogenous erythropoietin <50 mIU ml(-1) were significantly predictive of response (OR 2.496, 95% CI: 1.21-5.13).

View Article: PubMed Central - PubMed

Affiliation: Labo Hematologie Transplant, U.Z. Gasthuisberg, Leuven, Belgium. Marc.Boogaerts@med.kuleuven.ac.be

ABSTRACT
This open-label, prospective study was conducted to compare the impact of epoetin beta vs standard care on quality of life (QoL) in anaemic patients with lymphoid or solid tumour malignancies. A total of 262 anaemic patients (haemoglobin [Hb]or=2 g dl(-1) increase in Hb level without need of transfusion after the initial 4 weeks of treatment. Baseline to final visit changes in SF-36 PCS, FACT-F and VAS scores were significantly greater with epoetin beta than with standard care (P<0.05); changes in FACT-An subscale score tended to be greater with epoetin beta (P=0.076). Epoetin beta significantly increased Hb concentrations relative to standard care (responders: 47% vs 13%; P<0.001). Levels of endogenous erythropoietin <50 mIU ml(-1) were significantly predictive of response (OR 2.496, 95% CI: 1.21-5.13). Epoetin beta therapy significantly improves QoL compared with standard care in anaemic patients with solid tumours and lymphoid malignancies.

Show MeSH

Related in: MedlinePlus

Percentage of patients showing a clinical response to therapy defined as an increase in haemoglobin ⩾2 g dl−1 without the need for transfusion after the initial 4 weeks of treatment.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376376&req=5

fig2: Percentage of patients showing a clinical response to therapy defined as an increase in haemoglobin ⩾2 g dl−1 without the need for transfusion after the initial 4 weeks of treatment.

Mentions: Clinical response rates (increase in haemoglobin concentration of ⩾2 g dl−1 and/or increase to 12 g dl−1 without blood transfusion) and change in haemoglobin values from baseline


Impact of epoetin beta on quality of life in patients with malignant disease.

Boogaerts M, Coiffier B, Kainz C, Epoetin beta QOL Working Gro - Br. J. Cancer (2003)

Percentage of patients showing a clinical response to therapy defined as an increase in haemoglobin ⩾2 g dl−1 without the need for transfusion after the initial 4 weeks of treatment.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376376&req=5

fig2: Percentage of patients showing a clinical response to therapy defined as an increase in haemoglobin ⩾2 g dl−1 without the need for transfusion after the initial 4 weeks of treatment.
Mentions: Clinical response rates (increase in haemoglobin concentration of ⩾2 g dl−1 and/or increase to 12 g dl−1 without blood transfusion) and change in haemoglobin values from baseline

Bottom Line: Baseline to final visit changes in SF-36 PCS, FACT-F and VAS scores were significantly greater with epoetin beta than with standard care (P<0.05); changes in FACT-An subscale score tended to be greater with epoetin beta (P=0.076).Epoetin beta significantly increased Hb concentrations relative to standard care (responders: 47% vs 13%; P<0.001).Levels of endogenous erythropoietin <50 mIU ml(-1) were significantly predictive of response (OR 2.496, 95% CI: 1.21-5.13).

View Article: PubMed Central - PubMed

Affiliation: Labo Hematologie Transplant, U.Z. Gasthuisberg, Leuven, Belgium. Marc.Boogaerts@med.kuleuven.ac.be

ABSTRACT
This open-label, prospective study was conducted to compare the impact of epoetin beta vs standard care on quality of life (QoL) in anaemic patients with lymphoid or solid tumour malignancies. A total of 262 anaemic patients (haemoglobin [Hb]or=2 g dl(-1) increase in Hb level without need of transfusion after the initial 4 weeks of treatment. Baseline to final visit changes in SF-36 PCS, FACT-F and VAS scores were significantly greater with epoetin beta than with standard care (P<0.05); changes in FACT-An subscale score tended to be greater with epoetin beta (P=0.076). Epoetin beta significantly increased Hb concentrations relative to standard care (responders: 47% vs 13%; P<0.001). Levels of endogenous erythropoietin <50 mIU ml(-1) were significantly predictive of response (OR 2.496, 95% CI: 1.21-5.13). Epoetin beta therapy significantly improves QoL compared with standard care in anaemic patients with solid tumours and lymphoid malignancies.

Show MeSH
Related in: MedlinePlus